
Frontline Targeted Therapies Plus R-CHOP Boosts PFS in High-Risk B-Cell Lymphomas
CHICAGO — Combining two targeted therapies with standard-of-care chemotherapy extended progression-free survival (PFS) in patients with newly diagnosed B-cell lymphomas,



